AGILENT TECHNOLOGIES INC: TD COWEN RAISES TARGET PRICE TO $180 FROM $155

Agilent Technologies (A) has been upgraded to a Zacks Rank #2 (Buy), reflecting an upward trend in earnings estimates. The Zacks rating system, which is based on earnings estimate revisions, suggests a positive outlook for the company's stock price. Analysts have raised their estimates for Agilent by 3.4% over the past three months, with the company expected to earn $6.17 per share for the fiscal year ending October 2026.

Agilent (A) acquired Biocare for $950M. The company reported Q3 earnings, with shifts in debt and other financial metrics. The deal expands Agilent's diagnostics portfolio.

Agilent (A) reported Q3 2026 revenue of $1.88B, up 7.3% and exceeding guidance. EPS was $1.56, up 14% YoY. Strong performance driven by pharma, China growth, and Ignite strategy. Key growth areas include pharma, semiconductors, and AI infrastructure.

Agilent Technologies (A) reported Q3 2026 sales of $1.88B and net income of $362M, with EPS rising to $1.28. The company raised its full-year revenue and profit guidance, citing strong demand in pharma, China, and advanced materials, plus cost savings from its Ignite program. The updated outlook suggests margin benefits and product launches are offsetting cost pressures. Investors should note ongoing tariff and supply chain risks. Analysts' fair value estimates for Agilent range from $150.54 to

Agilent reported FY2026 Q3 earnings with EPS of $1.62 (8.7% above consensus) and revenue of $1.88B (2.2% above estimates). This marks the third consecutive quarter of EPS acceleration, with revenue growth of 6.7% in FY2025. However, gross margins slipped to 52.4% and free cash flow declined to $1.15B. The stock trades at 30.9x trailing P/E, with a fair-value estimate of $145.64, suggesting a 7.6% overvaluation.

Agilent Technologies (A) reported Q2 CY2026 revenue of $1.88B, up 8.1% YoY, beating estimates. Adjusted EPS was $1.62, 9% above consensus. Q3 revenue guidance is $1.99B, 1% above estimates. Management raised full-year EPS guidance to $6.20. Growth was driven by pharma, advanced materials, and China market recovery.